Beijing Tong Ren Tang Chinese Medicine Company Limited (TONGRENTANGCM) will convene its Annual General Meeting (AGM) on 10 June 2026 at 10:30 a.m. at 3 Dai King Street, Tai Po Industrial Estate, Hong Kong. Shareholders will vote on the following ordinary resolutions:

• 2025 Financial Statements: Consideration and adoption of the audited consolidated results, directors’ report and independent auditor’s report for the year ended 31 December 2025.

• Board Composition: Re-election of Executive Director Mr Wang Chi and Independent Non-Executive Directors Mr Tsang Yok Sing, Jasper and Mr Chan Ngai Chi, along with approval for the board to determine directors’ remuneration.

• Shareholder Returns: Approval of a final dividend of HK$0.37 per share and a special dividend of HK$0.03 per share, bringing the proposed total distribution to HK$0.40 per share for FY 2025.

• Auditor Re-appointment: Re-engagement of Ernst & Young as external auditor and authorization for the board to set its remuneration.

• Capital Mandates: – General mandate authorizing directors to issue new shares. – General mandate for share repurchases. – Extension of the issuance mandate by the number of shares repurchased under the buy-back mandate.

Proxy forms and supporting documents must reach Computershare Hong Kong Investor Services Limited no later than 48 hours before the meeting. Shareholders opting to attend in person may revoke previously lodged proxies upon registration at the AGM venue.